An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Double-Blind Study - INTENSE

Astellas Pharma Europe Ltd.0 sites250 target enrollmentStarted: January 19, 2010Last updated: February 11, 2013

Conditions

Drugs

Trial Snapshot

No summary available.

•1.= 18 years of age.
•2.Intra-abdominal infection requiring surgery and ICU stay.
•3.If CAI, duration of ICU stay of = 72 hrs (but not more than 120 hours), counted from the end of surgery, and a further expected duration of ICU stay of = 48 hours or more.
•4.If NAI, duration of ICU stay of = 48 hrs, counted from the end of surgery, and a further expected duration of ICU stay of = 48 hours or more.
•5.Female subject of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and must agree to maintain highly effective birth control during the study. contraceptives, some IUDs, sexual abstinence or vasectomised partner.
•6.The subject has been fully informed and has given written informed consent to participate in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Acute pancreatitis.
•2.Neutropenia (ANC < 1,000/mm3) at the time of randomization.
•3.Infected intra-peritoneal dialysis.
•4.Patients undergoing solid organ transplantation.
•5.Documented invasive candidiasis at the time of randomization.
•6.Expected survival < 48 hours.
•7.Any systemically active anti-fungal administered within 14 days prior to administration of the study drug.
•8.Allergy, hypersensitivity, or any serious reaction to an echinocandin anti-fungal or any of the study drug excipients.
•9.Currently receiving and/or has taken an investigational drug within 28 days prior to randomization..
•10.Pregnant woman or breast-feeding mother.
•11.‘Do Not Resuscitate’ order.
•12.The subject, in the opinion of the investigator, may find it difficult to adhere to the provisions of treatment and observation specified in the protocol.
•13.The subject has any clinical condition, diagnosis, symptomatology or ongoing investigation, which, in the opinion of the Investigator, contraindicates their participation in this study.

Sponsor